Press Releases

Date Title and Summary    
Toggle Summary Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
Patent Protection for RX-5902 (Supinoxin™) Extended until 2036 for Multiple Cancers including Triple Negative Breast Cancer
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Metastatic Pancreatic Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments Rexahn is Progressing Development of RX-3117 in Combination with Abraxane® in Newly Diagnosed Pancreatic
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
ROCKVILLE, Md., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will present clinical data from the completed Phase IIa
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018
ROCKVILLE, Md., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that Peter D. Suzdak, Ph.D., the Company's Chief Executive Officer,
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer
ROCKVILLE, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced the appointment of Douglas J.
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium
Supinoxin enhances the efficacy of immunotherapy in multiple preclinical models Supinoxin shows potent activity against patient-derived triple negative breast cancer (TNBC) tumors in preclinical models Supinoxin is currently being investigated in a Phase IIa clinical trial in patients with
View HTML Print
Toggle Summary Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, Ph.D., the Company's Chief Executive Officer, will
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer
ROCKVILLE, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), today announced that it has dosed the first patient in a Phase IIa clinical study of RX-3117 in combination with Abraxane® in patients newly diagnosed with metastatic pancreatic cancer who have had
View HTML Print
Toggle Summary Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Presented Preliminary Clinical Efficacy Data on RX-3117 in Bladder Cancer and Final Data on the Supinoxin™ Phase I Study at the ESMO Congress Strengthened Patent Position on RX-3117 and Supinoxin™ Received Positive Opinion on Orphan Drug Designation in Europe for RX-3117  Strengthened Financial
View HTML Print
Toggle Summary Rexahn Announces $8 Million Registered Direct Offering
ROCKVILLE, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 3.27 million shares of its common stock and warrants exercisable for up to
View HTML Print


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy